Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
02 January 2025 | Story Gerda-Marie van Rooyen | Photo Supplied
Prof Linus Franke
Leading the research in South Africa is Prof Linus Franke from the Department of Soil, Crop and Climate Sciences.

Scientists are actively pursuing the successful breeding of diploid hybrid potatoes from inbred lines. This is expected to revolutionise potato breeding as it holds the key to rapid genetic progress. It will introduce new varieties for commercialisation through seed. Currently, existing potato variants have a gene that renders self-pollinated seeds infertile.

Prof Linus Franke, an academic in the Department of Soil, Crop and Climate Sciences at the UFS, is leading the research in South Africa. “This technology allows the production of genetically uniform potato seed that is easy to transport and largely disease-free.” He says this differs from conventional breeding whereby only vegetative propagation is possible due to tetraploid varieties in potatoes. It also risks carrying pests and diseases from one generation to the next – leading to the accumulation of pests and diseases with each round of multiplication.

Seed innovation

Prof Franke explains that Solynta BV, a seed company based in the Netherlands that produces potato varieties that can be grown from seed, has included South Africa in their research efforts because it is one of Africa’s largest producers and exporters. Through his academic relationship with Wageningen University and Research, a Dutch institution renowned for its agricultural endeavours and food production, the UFS became involved in researching hybrid potatoes grown from seed.

Diploid seeds containing two sets of chromosomes allow easier gene manipulation to increase predictability and speedier genetic progress. The breeding approach enables the incorporation of tolerance to pests, diseases, abiotic stresses (cold, heat, drought) and other desired genetic traits.

Although Prof Franke is optimistic about this research, he is not blind to disadvantages. “Potato seeds are tiny and have little energy reserves, making it harder to grow potatoes from seed than from tubers.” He says potatoes from seed will take longer to cultivate than tubers, as farmers need to grow plantlets from seeds first, adding six weeks to the growing period. “It is possible that commercial farmers can grow potatoes directly from seed. Alternatively, perhaps more likely, specialised growers will produce tubers of potatoes from seed; these tubers are then sold as seed tubers to other potato farmers, who then continue their normal practices of producing potatoes for the market from tubers.”

Financial benefits

Prof Franke says farmers have reason to get excited. “Seed potatoes will reduce input costs, as varieties with enhanced tolerance to pests and diseases require less pesticides. Planting one hectare of potatoes requires three to four tonnes of potato tubers, but only one 25 g packet of potato seeds.” Since potatoes are a more valuable commodity than maize, this technology might also increase farmers’ income potential.

News Archive

National Department of Health invests R53.5 million in UFS laboratory
2016-02-04

Description: Dr Derek Litthauer Tags: Dr Derek Litthauer

Dr Derek Litthauer
Photo: Supplied

This year has started off on a high note for Dr Derek Litthauer and his team at the South African National Control Laboratory (NCL) for Biological Products. The National Department of Health has awarded the NCL a contract to the value of R53.5 million to continue testing vaccines for the next three years.

Vaccines are biological medicines used to ensure healthy populations by preventing many diseases. The World Health Organization (WHO) estimates that, worldwide, about 5.2 million children under six years old die annually. Of these deaths, 29% are vaccine preventable. Research has revealed that vaccines prevent about 6 million deaths each year globally. Safe and effective vaccines are essential public health tools, which are strictly regulated internationally. It is the NCL’s responsibility to perform quality control testing on all vaccines to be used on humans in South Africa.

This laboratory, the only one of its kind in Africa, receives samples of vaccines from manufacturers and importers for rigorous evaluation and testing. No vaccine may be used in South Africa without a release certificate issued by the Control Lab, certifying that the vaccine is suitable for human use.

The contract is a commitment to ensuring that only vaccines of the highest quality are used in South Africa.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept